Skip to main navigation Skip to search Skip to main content

Genotype-phenotype correlations of GFAP variants in type I Alexander disease subtypes

  • Tiziana Bachetti*
  • , Ylenia Vaia*
  • , Alice Grossi
  • , Francesca Rosamilia
  • , Enrico Bertini
  • , Francesco Nicita
  • , Deianira Bellitto
  • , Florian Eichler
  • , Geneviève Bernard
  • , Amanda Nagy
  • , Ayelet Zerem
  • , Morteza Heidari
  • , Ali Reza Tavasoli
  • , Isabella Moroni
  • , Isabella Ceccherini
  • , Davide Tonduti
  • *Corresponding author for this work
  • University and San Martino Hospital of Genoa
  • Ospedale dei Bambini Vittore Buzzi
  • University of Milan
  • IRCCS Istituto Giannina Gaslini - Genova
  • IRCCS Ospedale pediatrico Bambino Gesù - Roma
  • Massachusetts General Hospital
  • Harvard University
  • McGill University
  • Tehran University of Medical Sciences
  • Phoenix Children's Hospital
  • IRCCS Fondazione Istituto Neurologico Carlo Besta - Milano

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Introduction: Alexander disease (AxD) is a rare and progressive leukodystrophy caused by variants in the Glial Fibrillary Acidic Protein (GFAP) gene. AxD presents as Type I and Type II, based on clinical and neuroradiological features. However, Type I patients variable disease progression has led to sub-classify them into subtypes Ia-Ib-Ic-Id. Our study investigated genotype-phenotype correlations in Type I AxD across these subtypes. Methods: A cohort of 74 genetically confirmed Type I AxD patients was analysed, with variants classified according to the clinical subtypes Ia, Ib, Ic, and Id. Genotypic–phenotypic correlations were explored both across all subtype groups and in stratified analyses based on patients' ability to achieve independent ambulation versus those who never acquired this milestone. To investigate the functional consequences of a representative variant, in vitro assays were performed. Selected mutant GFAP protein was expressed and their ability to assemble into intermediate filament networks was assessed. Results: The study revealed a progressive decrease in GFAP allelic heterogeneity across disease subtypes from Ia to Id. Additionally, GFAP pathogenic variants in exon 1 were more frequent in milder forms, whereas mutations in exon 4 were predominantly observed in severe phenotypes. In addition, changes at p.R239 and p.R79 residues showed an opposite trend, with variants affecting p.R239 never detected in Id subtype, while variants affecting p.R79 never detected in Ia. Specific aminoacidic changes at the p.R79 residue were able to stratify patients based on ability to acquire independent ambulation or not. Furthermore, the distribution of Combined Annotation Dependent Depletion (CADD) scores showed an inverse correlation with the acquisition of autonomous ambulation. Conclusions: These results suggest that specific GFAP variants could be potential predictors for disease progression in Type I AxD, supporting patients' subclassification and underscoring the importance of considering both genetic and clinical factors in AxD management, particularly as therapeutic interventions are being developed.

Original languageEnglish
Article number109689
JournalMolecular Genetics and Metabolism
Volume147
Issue number1
DOIs
StatePublished - Jan 2026

Funding

FundersFunder number
Associazione Più Unici Che Rari
Santé
AxD Association
Più Unici che Rari Onlus
Ionis Pharmaceuticals
Canadian Institutes of Health Research2022–2025, 2025–2029, 2017–2022
Ministero della SaluteU733A 2024

    Keywords

    • Alexander disease
    • GFAP
    • Gene variant
    • Genotype-phenotype correlation
    • Neurodegeneration

    Fingerprint

    Dive into the research topics of 'Genotype-phenotype correlations of GFAP variants in type I Alexander disease subtypes'. Together they form a unique fingerprint.

    Cite this